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1. Introduction 
Hypoxia, a partial pressure of oxygen (pO2) below physiological needs, is a limiting factor 
affecting the efficiency of radiotherapy. Indeed, the reaction of reactive oxygen species 
(ROS, produced by water radiolysis) with DNA is readily reversible unless oxygen stabilizes 
the DNA lesion. While normal tissue oxygenation is around 40 mm Hg, both rodent and 
human tumors possess regions of tissue oxygenation below 10 mm Hg, at which tumor cells 
become increasingly resistant to radiation damage (radiobiological hypoxia) (Gray, 1953). 
Because of this so-called “oxygen enhancement effect”, the radiation dose required to 
achieve the same biologic effect is about three times higher in the absence of oxygen than in 
the presence of normal levels of oxygen (Gray et al., 1953; Horsman & van der Kogel, 2009). 
Hypoxic tumor cells, which are therefore more resistant to radiotherapy than well 
oxygenated ones, remain clonogenic and contribute to the therapeutic outcome of 
fractionated radiotherapy (Rojas et al., 1992).  
Tumor hypoxia results from the imbalance between oxygen delivery by poorly efficient 
blood vessels and oxygen consumption by tumor cells with high metabolic activities. On the 
one hand, oxygen delivery is impaired by structural abnormalities present in the tumor 
vasculature (Munn, 2003). They include caliber variations with dilated and narrowed single 
branches of tumor vessels, non-hierarchical vascular networks, disturbed precapillary 
architecture, and incomplete vascular walls. These structural abnormalities cause numerous 
functional impairments, i.e. increased transcapillary permeability, increased vascular 
permeability, interstitial hypertension, and increased flow resistance (Boucher et al., 1996; 
McDonald & Baluk, 2002). It is however important to note that, although hastily formed 
immature tumor microvessels lack smooth muscle layer(s) and are therefore unable to 
provide autoregulation, it is not uncommon to find mature blood vessels with smooth 
muscle layers and neural junctions inside slow-growing tumors (e.g. most human tumors) 
(Feron, 2004). On the other hand, the altered tumor cell metabolism with elevated metabolic 
rates also contributes to the occurrence of hypoxic regions in tumors and further causes 
extracellular acidification. Tumor hypoxia occurs in two ways: chronic hypoxia (or 
diffusion-limited hypoxia), and acute hypoxia (or perfusion-limited or fluctuating hypoxia). 
Chronic hypoxia has classically been thought to result from long diffusion distances 
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between tumor vessels as the consequence of the more rapid expansion of tumors cells than 
that of the supporting vasculature (Vaupel et al., 1989). It is now well established that steep 
longitudinal gradients of pO2 along the vascular tree, as opposed to radial diffusion of 
oxygen, can largely contribute to deficiencies in tumor oxygen supply (Dewhirst et al., 1999). 
The origin of acute hypoxia in tumors is not firmly established. The commonly held view 
has been that acute hypoxia results primarily from vascular stasis, which stems from one of 
three causes: 1) vascular collapse in regions of high tumor interstitial pressure, 2) vessel 
plugging by leukocytes, and 3) impingement of tumor cells on the vascular lumen. It has 
been demonstrated that temporal instability in tumor red blood cell flux could lead to 
transient hypoxia (Kimura et al., 1996), and Dewhirst linked temporal changes in 
microvessel red blood cell flux to changes in the oxygen content in the same vessel 
(Dewhirst et al., 1996). Factors that may contribute to flow fluctuations include arteriolar 
vasomotion and rapid vascular modeling (Baudelet et al., 2004, 2006; Dewhirst et al., 1996; 
Patan et al., 1996). More recent studies indicate a widespread presence of fluctuating 
hypoxia in solid tumors (Cardena-Navia et al., 2008). 
The effect of tumor hypoxia on the response to treatment by ionizing radiation has been 
demonstrated in a multitude of experimental studies. In a series of clinical studies in the 
early nineties, Vaupel and others showed definitively that measurements of pO2 by 
polarographic microelectrodes provided useful criteria for predicting the response of 
tumors to radiation therapy (Gatenby et al., 1988; Hockel et al., 1993; Okunieff et al., 1993; 
Stone et al., 1993; Thomas et al., 1994). These results stimulated considerable efforts in 
defining and evaluating therapeutic approaches designed to overcome tumor hypoxia as 
source of resistance (Horsman & van der Kogel, 2009). A particular area under focus is thus 
to combine radiotherapy with treatments that increase tumor pO2. Other approaches consist 
to chemically radiosensitize hypoxic cells or alternatively to exploit hypoxia as a mean to 
selectively kill the resistant population of hypoxic cells. Before the advent of imaging 
methods able to provide non-invasively oxygen estimation, animal and clinical studies were 
generally designed to evaluate the effect of a given treatment on tumor pO2 as measured by 
Eppendorf or histological markers of tumor hypoxia. The clinical end points were generally 
locoregional control and survival. Modifiers of oxygen delivery tested in clinical trials 
included hyperbaric oxygen therapy (HBO), oxygen and carbogen breathing. Hypoxic cell 
radiosensitizers (possessing a selective toxicity for the radioresistant hypoxic cells) tested in 
clinical trials included metronidazole, misonidazole, nimorazole, and tirapazamine. In a 
systematic review, J. Overgaard (2007) identified 10,108 patients in 86 randomized trials 
designed to modify tumor hypoxia in patients treated with curative attempted primary 
radiation therapy alone. Overall modification of tumor hypoxia significantly improved the 
effect of radiotherapy for the outcome of locoregional control and with an associated 
significant overall survival benefit. No significant influence was found on the incidence of 
distant metastases or on the risk of radiation-related complications. From this meta-analysis, 
the authors concluded in 2007 that “Ample data exist to support a high level of evidence for 
the benefit of hypoxic modification. However, hypoxic modification still has no impact on 
general clinical practice”. 
Currently, the most advanced therapeutic interventions used in the clinic to target tumor 
hypoxia are either the DAHANCA (Danish head and neck cancer) trial, the application of 
the ARCON (Accelerated radiotherapy, carbogen and nicotinamide) protocol, and phase III 
studies with Tirapazamine. In the DAHANCA phase III study, nimorazole has been used as 
hypoxic radiosensitizer on 422 patients, and it was shown that this compound improves the 
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effect of radiotherapeutic management in head and neck cancer (Overgaard et al., 1998). 
Since these results, nimorazole administration became part of the standard irradiation 
protocol for Head and Neck cancer in Denmark. However, these findings have had no 
impact on general clinical practice except for Denmark because earlier generations of these 
agents induced rather severe peripheral neuropathy and because nearly all of the individual 
phase III trials yielded negative or inconclusive results (Ang, 2010). The ARCON protocol 
consists in the combination of accelerated radiotherapy to overcome tumor cell proliferation, 
carbogen breathing to overcome diffusion-limited hypoxia, and nicotinamide to minimize 
capillary bed shutdown and thereby reduce perfusion-related acute hypoxia. Phase I and II 
clinical trials have shown the feasibility and tolerability of the treatment and have produced 
promising results in term of tumor control, in particular in cancer of the head and neck and 
bladder (Kaanders et al., 2002). A large improvement in survival was demonstrated using 
this approach during radiotherapy for bladder cancer. The randomized multicentre phase III 
trial, designed and coordinated at Mount Vernon Cancer Centre, demonstrated a 13% 
benefit in overall survival when radiotherapy was combined with carbogen and 
nicotinamide compared to radiotherapy alone (ASTRO, 2009). Results from a large phase III 
trial launched to test this regimen will become available within the next 2 years. Finally, 
Tirapazamine (TPZ) has attracted interest after preclinical studies showing that in addition 
to augmenting the cytotoxicity of both radiation and cisplatin, this compound selectively 
kills hypoxic cells (Rischin et al., 2001; 2005). Phase I and II studies of the combination of 
TPZ with radiation and cisplatin were performed on patients with locally advanced head 
and neck carcinoma. On the basis of the phase II data, a large international phase III trial 
was launched (Peters et al., 2010). Surprisingly, the combination did not show any evidence 
of improvement in overall survival. Nevertheless, patients were not previously screened for 
tumor hypoxia, the study was multicentric with some centers enrolling fewer than five 
patients and a consequent decrease in the quality of radiotherapy planning and delivery 
which can have dramatic consequences on outcome (Ang, 2010).  
This chapter will explore 2 strategies to radiosensitize tumors to X-rays: to increase oxygen 
delivery by exploiting the reactivity of mature tumor vessels (the so-called ‘provascular’ 
approach) and to decrease oxygen consumption by tumor cells. The goal of the provascular 
approach is to temporarily increase tumor perfusion and oxygenation through 
pharmacological interventions. Accordingly, radiotherapy could benefit from tumor 
reoxygenation whereas a decrease in interstitial pressure could facilitate tumor accessibility 
to circulating drugs. Alternatively, a second approach is to decrease the oxygen 
consumption by tumor cells since theoretical modeling studies demonstrated that reducing 
O2 consumption was far more efficient at reducing tumor hypoxia than increasing blood 
pO2 or flow (Secomb et al., 1995). We will also describe attempts to combine both 
approaches that can be considered as complementary strategies. The evaluation and 
validation of these adjuvant therapies require imaging techniques capable to accurately 
monitor tumor perfusion and oxygenation.  
From the clinical analyses cited above, it also appeared that the variation in the results 
among the trials reflects a considerable heterogeneity among tumors and that patient 
individualization would be mandatory for the success of such therapeutic approach. There 
is therefore an essential need to predict individually the presence of hypoxic regions in 
tumors. Based on individual tumor characteristics and/or the ability to alleviate tumor 
hypoxia, it will become possible to adapt the individual treatment either by delivering 
optimal radiation doses into the resistant areas or by delivering an associated treatment for 
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potentiating the efficacy of radiation treatments. In the early nineties, invasive techniques 
such as polarographic electrodes have been used in clinical studies to definitely establish the 
value of hypoxia as a predictive marker of the response of tumors to irradiation. Although 
this method was successful in demonstrating the central role played by tumor hypoxia in 
the clinical response to radiation therapy, it has never been used in standard clinical practice 
because of its invasiveness and the difficulty to systematically carry out longitudinal studies 
in individual patients. Fortunately, it is now possible to estimate tumor oxygenation by 
using minimally or non invasive techniques. This will be the purpose of the last part of this 
chapter.  
2. Improving oxygen delivery to the tumor: The provascular approach 
Tumors are highly heterogeneous and this heterogeneity extends to the tumor vasculature 
(see introduction). Beside neovessels that are the target of anti-angiogenic agents, human 
and rodent tumors also contain blood vessels that are structurally mature (Mattson et al., 
1978; Peterson & Mattson, 1984). These vessels possess the minimal contractile features 
(such as pericytes or vascular smooth muscle cells) endowing them with vasocontractile 
properties. The intrinsic reactivity of tumor-feeding vessels modulates oxygen delivery and 
the accessibility of circulating drugs to the tumor. A selective and transient dilation of these 
vessels should thus improve the tumor response to radiotherapy (which depends on tumor 
oxygenation) and chemotherapy (which depends on perfusion and on the vascular exchange 
area). We termed this approach ‘provascular’ to contrast with antivascular and anti-
angiogenic approaches that are destructive by nature (Sonveaux, 2008). The net effect of 
systemic vasodilation on tumor pO2 is unpredictable because it primarily depends on the 
arrangement of vessels (in series or in parallel) between the tumor and surrounding host 
tissues (Zlotecki et al., 1995). The key issue to resolve is thus to identify tumor-selective 
vasodilators. Treatment optimization would also require to monitor on individual bases the 
tumor response to treatment, preferentially using early surrogate, predictive and non-
invasive markers. 
2.1 Nitric Oxide (NO) and endothelin-1 (ET1) related strategies 
Physiologically, the vascular tone is determined by the balance between nitric oxide (NO, a 
potent vasodilator) and endothelin-1 (ET1, a potent vasoconstrictor) (Sonveaux & Feron, 
2005a). A number of studies have explored the functionality and the provascular 
exploitability of these 2 systems, as described below. 
2.1.1 Exogenous and endogenous NO 
NO was initially investigated for its vasodilatory activity and NO-donors were anticipated 
to improve the therapeutic efficacy of chemo- and radiotherapy upon combinational 
delivery (Sonveaux et al., 2009). We first considered the effect of the application of 
exogenous NO on tumor hemodynamic parameters and radiation response. This was 
performed by systemic administration of NO donor compounds, including isosorbide 
dinitrate (Jordan et al., 2000), Xanthinol Nicotinate (Segers et al., 2010), and S-nitroso-
captopril (Jordan et al., 2010a). The stimulation of the production of endogenous NO was 
also achieved by administration of insulin (Jordan et al., 2002). All treatments resulted in a 
transient acute improvement of experimental tumor oxygenation with a consecutive 
increase in tumor radiosensitivity upon sequential administration of X-rays during the 
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reoxygenation window identified for each tumor model (Jordan et al., 2010a). The 
reoxygenation effect was shown to be due to an increase in tumor blood flow for Isosorbide 
Dinitrate, Xanthinol Nicotinate and S-nitrosocaptopril, using either dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI), where the number of perfused voxels 
and/or Ktrans, Kep, or Vp parameters was increased (see 5.2.1) , or patent blue staining 
(Jordan & Gallez, 2010b). Importantly, for some co-treatments, the increase in blood flow 
occurred concomitantly with a decrease in the rate of oxygen consumption by tumor cells.  
Inhibition of tumor cell respiration is the main mechanism accounting for insulin-induced 
tumor reoxygenation (see below).  
Endogenous NO is produced by a series of enzymes collectively termed NO-synthases 
(NOS). The endothelial isoform, eNOS, is adapted for the local stimulation of vasodilation 
following a response to stimuli that release calcium from intracellular stores and promote a 
calcium-calmodulin-dependent release of eNOS from its inhibitory complex with caveolin-1 
(Cav-1) (Arnold et al., 1977; Michel et al., 1997). This mode of activation allows the transient 
production of micromolar amounts of NO responsible for vasodilatation. Using myography, 
we showed that this system is insensitive to classical eNOS stimulators (such as 
acetylcholine) selectively in tumor arterioles, thus suggesting that strategies able to restore 
eNOS activity would selectively target tumor vessels (Sonveaux et al., 2002). Among 
different treatments, we have found that ionizing radiations themselves were able to restore 
the normal vasodilatory properties of tumor vessels. X-rays, through the production of 
reactive oxygen species (ROS), indeed induce an increase in eNOS expression concomitantly 
with a decrease in Cav-1 expression, which removes a functional brake promoting eNOS 
activation (Sonveaux et al., 2002, 2009). Irradiations further stimulate NO production 
through the ROS-dependent activation of the PI3 kinase pathway, a well described pathway 
supporting Akt-mediated eNOS phosphorylation (on Ser1177, human sequence) and 
activation (Sonveaux et al., 2003, 2007a). We documented that radiation-induced 
vasodilation takes an active part in the antitumor effects of X-rays by showing that eNOS 
inhibition between the first and second irradiation of a clinical regimen of fractionated 
radiotherapy results in the total loss of the antitumor efficacy of the second dose, whereas 
eNOS inhibition before a single dose does not preclude cytotoxic effects (Sonveaux et al., 
2002). Active vasodilation after each of the consecutive doses of fractionated radiotherapy is 
associated with a window of tumor reoxygenation that offers a scientific rationale for the 
clinical use of radiotherapy in its fractionated mode.  
2.1.2 S-nitrosylated hemoglobin and nitrites 
A smart delivery of exogenous NO would help to resolve the Steal Effect, a process through 
which systemic vasodilation may in fact reduce tumor perfusion and oxygenation by 
redirecting blood to normal blood vessels that are generally more sensitive to vasoactive 
treatments and constitute a denser network (Zlotecki et al., 1995). Using hemoglobin (Hb) is 
an interesting approach because Hb is a physiological NO carrier (in the form of S-
nitrosothiol) poised to deliver NO selectively in hypoxic tissues such as tumors (Sonveaux et 
al., 2005b). NO delivery, indeed, is possible only after the conformational change associated 
with Hb deoxygenation (Jia et al., 1996; McMahon et al., 2002; Stamler et al., 1997). Using 
cell-free human S-nitrosylated Hb (SNO-Hb) in rats, we documented a transient increase in 
tumor perfusion, but only when SNO-Hb was delivered in oxygenated blood (i.e., intra-
arteriolar injection or intravenous injection concomitantly with carbogen breathing) 
(Sonveaux et al., 2005b). In deoxygenated blood, SNO-Hb would otherwise readily 
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deoxygenate and release NO at the site of delivery. While increased tumor perfusion at low 
dose SNO-Hb is primarily attributable to central effects (i.e., baroreceptor inhibition), SNO-
Hb at higher doses could act as a tumor-selective vasodilator and could therefore be used as 
a radiosensitizing treatment. Inhalation of the NO-donor gas ethyl nitrite, which promotes 
the S-nitrosylation of intra-erythrocytic Hb in the lungs, could have the same effects while 
minimizing toxic side effects associated with the administration of naked Hb (Moya et al., 
2002; Sonveaux et al., 2007b). 
While the use of SNO-Hb exploits hypoxia as a mean to selectively deliver NO to tumors, 
one can also take advantage of the low pH coupled to the high metabolic activities of many 
solid tumors. Nitrites for example can be reduced to NO either by enzymatic catalysis 
(nitrite reductase activities of xanthine oxidase, eNOS and Hb) or by non enzymatic 
disproportionation, and these processes are facilitated in an acidic microenvironment 
(Angelo et al., 2006; Godber et al., 2000; Modin et al., 2001; Vanin et al., 2007; Zweier et al., 
1999). They have been used clinically as an antidote for cyanide poisoning (Holland & 
Kozlowski, 1986), which also indicates that they can be safely administrated to humans. We 
therefore tested whether the low pH of tumors (on average pH 6.7) could be exploited to 
generate NO from nitrites selectively in tumors. We observed ex vivo that nitrite-induced 
vasodilation was more pronounced at pH 6.7 compared to pH 7.4 (Frerart et al., 2008). We 
also found that the bioactivity of nitrites at low pH encompassed NO-mediated inhibition of 
tumor cell respiration, which indicates that the robust and transient increase in tumor pO2 
after nitrite delivery to mice is the result of the combination of vasoactive and metabolic 
responses. When administered to reach a plasma concentration of 100 µM in mice, nitrites 
sensitized tumors to radiotherapy (Frerart et al., 2008). Further clinical applications are 
however confronted to financial issues: clinical trials are now warranted whereas nitrites or 
their use in cancer therapy can not be patented.  
2.1.3 Endothelin-1 inhibitors 
Endothelin-1 (ET-1) is a strong vasoconstrictor and an autocrine growth factor produced by 
tumor cells (Haynes & Webb, 1994; Shichiri et al., 1991). It has a key role in the 
accommodation of vasoactive blood vessels to variations in intraluminal pressure: ET-1 
mediates the myogenic tone, a vasoconstriction that buffers perfusion changes when the 
blood pressure increases (Huang & Koller, 1997). In tumors, the constant exposure of 
arterioles to ET-1 in vivo results in an increased myogenic tone that can be detected ex vivo 
(Sonveaux et al., 2004). We reasoned that it constituted a reserve for vasorelaxation that 
could be exploited to sensitize tumors to radio- and chemotherapy. ET-1 induces 
vasoconstriction when binding to ETA receptors expressed by contractile vascular cells 
(Maguire & Davenport, 1995). Using the ETA antagonist BQ123, we observed ex vivo a 
vasodilation selectively in tumor vessels (compared to size-matched vessels from 
nonmalignant tissues) that translated in vivo into increased tumor perfusion and 
oxygenation (Sonveaux et al., 2004). Both responses were tumor-selective and transient. 
BQ123 as a pretreatment therefore improved the antitumor effects of X-ray radiotherapy and 
cyclophosphamide (after systemic delivery) (Martinive et al., 2006; Sonveaux et al., 2004).  
2.2 Normalization effect of anti-angiogenic agents 
Given that anti-angiogenic agents will likely be combined with radiation therapy, it is 
critical to understand alterations in tumor oxygenation and perfusion, as well as to define 
www.intechopen.com
Targeting Tumor Perfusion and Oxygenation Modulates 
Hypoxia and Cancer Sensitivity to Radiotherapy and Systemic Therapies 
 
295 
optimal time points for the delivery of radiation. Our group previously studied the 
modifications in the tumor environment early after treatment with the anti-angiogenic agent 
thalidomide, with a special focus on a possible normalization of the tumor vasculature (Jain, 
2001; Tong et al., 2004) that could be beneficial for radiotherapy. Our results showed an 
increase in tumor pO2 during the first 2 days of thalidomide treatment, which was likely the 
result of the ability of thalidomide to modify tumor microenvironmental parameters such as 
the vascular supply and tumor perfusion, as shown by DCE-MRI (see 5.2.1) and histological 
analysis using the endothelial marker CD31 (Ansiaux et al., 2005). Indeed, the histological 
analysis revealed profound modifications in the vascular supply: a reduction in the number 
of tumor microvessels after thalidomide treatment together with a dilation of the remaining 
vessels with no decrease in the tumor vascular density. The perfusion measured by DCE-
MRI showed an increased plasma volume fraction (see 5.2.1), which could be explained by 
the shift to larger blood vessel diameters as observed in histology analysis, perhaps due to 
compensation for the loss of small vessels. Interestingly, similar observations were not 
obtained using more specific anti-angiogenic agents such as SU-5416 or ZD-6474 (Ansiaux et 
al., 2006; 2009). For these compounds, tumor reoxygenation was rather due to a decrease in 
the rate of oxygen consumption by tumor cell and no normalization effect was observed in 
the tumor models under study (see below). We hypothesized that specific inhibition of 
vascular endothelial growth factor (VEGF) signaling via VEGFR2 by SU-5416 or ZD-6474 
may have been compensated by another angiogenic pathway such as basic fibroblast growth 
factor (bFGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF)-, 
or Tie-2 signaling (Folkman et al., 2001; Stratmann et al., 1998); contrary to thalidomide 
which acts on different angiogenic pathways. It is nevertheless important to note that these 
findings are specific to the tumor models under study, since ZD-6474 was described earlier 
to be able to decrease both flow and permeability in human colon tumors (Bradley et al., 
2008) and was able to induce transient normalization of the vasculature in gliomas (Claes et 
al., 2008). 
3. Decreasing oxygen consumption by tumor cells 
Tumor oxygenation is a matter of supply and demand. Whereas the provascular strategy 
intends to improve oxygen supply, several strategies are aimed at decreasing oxygen 
consumption by tumor cells rendering molecular O2 available for the stabilization of 
radiation-induced DNA damage. Indeed, theoretical modeling studies demonstrated that 
reducing O2 consumption could be more efficient at reducing tumor hypoxia than 
increasing blood pO2 or flow (Secomb, 1995). Two main targets can be considered for 
inhibiting oxygen consumption: (i) direct interference with the mitochondrial respiratory 
chain (at different levels), and (ii) modulation of the redox status to change the 
mitochondrial membrane potential (Pilkington et al., 2008); the final aim being a subsequent 
increase in tumor pO2 and enhancement of the efficacy of radiotherapy. 
In contrast to provascular strategies, Laser Doppler flowmetry, DCE-MRI and electron 
paramagnetic resonance (EPR) oximetry have revealed that the radiosensitizing effects of 
these treatments are primarily caused by a decrease in the rate of oxygen consumption by 
tumor cells, thus allowing oxygen to be redirected from a metabolic fate to the stabilization 
of DNA lesions. Indeed, apart from NO donors, all the treatments described below did not 
show any significant increase in tumor blood flow concomitant to the increase in tumor 
oxygenation. Some of them even showed a decrease in tumor blood flow that was 
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counteracted by the dramatic decrease in oxygen consumption by tumor cells (i.e. insulin 
and NS-398). In addition, regarding NO-mediated treatments, our models showed that the 
radiotherapeutic response not only depended on the tumor pO2 but also on the net level of 
NO achieved at the time of irradiation, NO itself being able to stabilize irradiation-induced 
DNA lesions in vivo (Jordan et al., 2004). 
The first drug that was described to inhibit oxygen consumption in tumors was meta-
iodobenzylguanidine (MIBG), which causes an inhibition of the mitochondrial site I electron 
transfer, inhibition of NAD(P)H oxidation, and is described to alter tumor glycolysis by 
inhibiting oxygen consumption (Biaglow et al., 1998). We consecutively focused on different 
innovative treatments that may alter oxygen consumption by tumor cells, as listed below. 
3.1 Insulin 
This hormone was known to increase blood flow in human skeletal muscle and was 
postulated to be an important modulator of tumor oxygenation (Jordan et al., 2002). Indeed, 
we showed that insulin had a profound effect on tumor oxygenation that was not due to an 
increase in tumor blood flow but to a decrease in tumor cell oxygen consumption. The 
increase in tumor oxygenation resulted in an important enhancement in the sensitivity of 
tumors to irradiation. The likely scenario involves a stimulation of eNOS and a consequent 
increase in NO release. As NO regulates mitochondrial respiration by virtue of reversible 
interactions with cytochrome c oxidase (complex IV), an increase in NO release 
consequently decreased cell respiration (Jordan et al., 2002). A preclinical study confirmed 
the dose-dependant increase in tumor oxygenation and radiation sensitivity by insulin, 
without any increase in the radiation toxicity for normal tissues (Jordan et al., 2006a). 
3.2 Glucocorticoids 
Earlier work had demonstrated that the administration of cortisone to rats resulted in both 
the inhibition of oxygen consumption and the uncoupling of oxidative phosphorylation in 
liver mitochondria (Kimberg et al., 1968). Glucocorticoids seemed to decrease the 
cytochrome c oxidase (complex IV) activity of isolated rat kidney mitochondria by a direct 
mechanism (Simon et al., 1998). Our group showed an important increase in tumor 
oxygenation induced by an effect on oxygen consumption. Decreased oxygen consumption 
could be explained by the capacity of glucocorticoids to inhibit cytochrome c oxidase of the 
mitochondrial respiratory chain. The result of this increase in tumor oxygenation was an 
improvement of the radiation efficacy by a factor of 1.7 (Crokart et al., 2007). 
3.3 Anti-inflammatory drugs 
Several reports indicated that many non-steroidal anti-inflammatory drugs (NSAIDs) 
uncouple mitochondrial oxidative phosphorylation with important consequences on cell 
oxygen consumption. However, it was suggested that the response was dependent on the 
dose as well as on the type of NSAIDs. For the first time, our group reported that the 
administration of NSAIDs induced a dramatic increase in tumor oxygenation explained by 
reduced oxygen consumption. An increase in the tumor response was observed when the 
irradiation was applied at the time of maximal reoxygenation (Crokart et al., 2005). 
3.4 Thyroid hormones 
Chronic alteration in the thyroid status has been shown to affect mitochondrial oxygen 
consumption in skeletal muscle (Gredilla et al., 2001). Also, studies have demonstrated that 
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hypothyroidism slows down the neoplastic process, whereas administration of a thyroid 
hormone preparation restores tumor growth rates (Mishkin et al., 1981; Shoemaker & 
Dagher, 1979; Theodossiou et al., 1999). In humans, several case reports have indicated a 
prolonged survival in the presence of hypothyroidism (Cristofanilli et al., 2005; Hercbergs & 
Leith, 1993). Moreover, a decrease in the thyroid function may also serve to favorably 
influence the response to treatment. Finally, patients presented an enhanced response rate to 
chemotherapy and survived significantly longer under hypothyroidism (Hercbergs et al., 
2003). Our group recently demonstrated that the thyroid status is associated with a 
significant change in tumor radiosensitivity since the regrowth delay was increased in 
hypothyroid mice compared to euthyroid mice. Mechanistically, we demonstrated that the 
higher level of tumor oxygenation in hypothyroid mice results from a significant reduction 
in the oxygen consumption rate of tumors (Jordan et al., 2007). 
3.5 NO donors 
We recently tested whether S-nitrosocaptopril, a molecule combining a NO donor and an 
angiotensin converting enzyme inhibitor (ACE inhibitor), could temporarily improve the 
hemodynamic status of experimental tumors. We identified a time window during which 
tumor oxygenation was improved, as a result of a combined effect on tumor blood flow and 
oxygen consumption. Consequently, the administration of S-nitrosocaptopril contributed to 
the increase in efficacy of radiation therapy, an effect that was not observed with captopril 
alone (Jordan et al., 2010a).  
3.6 Anti-angiogenic agents 
As stated earlier, two anti-angiogenic agents, SU-5416 and ZD-6474, have also been 
identified as potent inhibitors of oxygen consumption (Ansiaux et al., 2007, 2009). Our major 
findings regarding those specific anti-angiogenic agents were the following: (a) SU-5416 and 
ZD-67474 both induce an increase in tumor oxygenation at an early phase of treatment (after 
2 days of daily injections); (b) this tumor reoxygenation can be exploited to increase the 
efficacy of combined radiotherapy; (c) the mechanism of increase in tumor oxygenation does 
not involve a ‘‘normalization’’ of the tumor vasculature as described previously for 
thalidomide in the same tumor model (Ansiaux et al., 2005) but is consistent with the 
decrease in the rate of oxygen consumption by the tumor cells. Indeed, at this early stage of 
the treatment, no apparent remodeling of the tumor vasculature and no changes in tumor 
perfusion and permeability parameters were observed, using histological and DCE-MRI 
analysis, respectively. We however demonstrated a reduction in tumor oxygen consumption 
after those treatments. The reduction factor in oxygen consumption observed was sufficient 
to abolish tumor hypoxia, as we reported previously using the treatments listed above.  
4. Hyperthermia: Combining provascular and oxygen consumption effects in a single 
treatment 
Hyperthermia is a potent adjuvant therapy with radiotherapy and chemotherapy, and the 
perfect illustration of a strategy combining transient, local vasodilatation with the inhibition 
of tumor cell respiration. The heat treatment consists of elevating the temperature of tumors 
to a supra-physiological range of 40°C to 45°C at which tumor reoxygneation occurs with 
limited skin toxicity. Hyperthermia induces a graded response in tissues characterized by 
decreased oxygen consumption at temperatures ≥ 40°C, vasodilatation between 41°C and 
41.5°C, and vascular damage above 42°C. Although direct tumor cell killing was 
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demonstrated in vitro at higher temperatures, long-term tumor control has never been 
demonstrated using hyperthermia as the sole treatment modality. Vasodilation only 
modestly contributes to tumor reoxygenation at the low thermal doses. Increased pO2 rather 
primarily results from changes in oxygen consumption in the target cells, and at least two 
different processes have been identified to contribute to this response. It is now well 
demonstrated that an important target of heat is proteins among which enzymes of the 
respiratory chain are more sensitive to heat inactivation/denaturation than glycolytic 
enzymes (Lepock et al., 1987; Kelleher et al., 1995). But the inhibition of mitochondrial 
respiration by heat lasts longer than the turnover time of respiratory enzymes, suggesting 
the existence of an additional mechanism. Dewhirst in collaboration with our group (Moon 
et al., 2010) recently demonstrated that mild hyperthermia activates the transcription factor 
hypoxia-inducible factor 1 (HIF-1) through an hypoxia-independent mechanism involving 
the sequential activation of Extracellular signal-Regulated Kinases (ERK) by heat shock, 
ERK-induced upregulation of the expression of the Nox1 subunit of NAD(P)H oxidase, 
increased ROS production by NAD(P)H oxidase, ROS-induced HIF-1 protein stabilization, 
and, ultimately, HIF-1 activation. HIF-1 target genes include most glycolytic enzymes and 
transporters as well as major pro-angiogenic molecules such as VEGF. Among these genes, 
we showed that pyruvate dehydrogenase kinase 1 (PDK1) largely mediates the inhibition of 
mitochondrial respiration by heat in tumor cells through inhibiting pyruvate dehydrogenase 
(PDH), i.e., the enzyme coupling glycolysis to the tricarboxylic acid (TCA) cycle (Moon et al., 
2010). Furthermore, consistent with the increase in VEGF expression that we also observed in 
heat-treated tumors, we documented an increased vascular density in perfused tumor areas 
where oxygen is extracted from the blood. Tumor reoxygenation by mild hyperthermia is thus 
a multifaceted process involving the combination of decreased O2 consumption by tumor cells 
and increased O2 delivery by blood vessels. This and the fact that reoxygenation occurs at 
thermal doses lower than those inducing vascular damage justifies the use of mild 
hyperthermia as a combination treatment notably with radiotherapy. Although several clinical 
trials have confirmed that combining heat and radiotherapy is indeed associated with better 
patient treatment outcome (Brizel et al., 1996; Jones et al., 2003, 2005; Vujaskovic et al., 2003), 
the future clinical development of hyperthermia strongly relies on designing tools allowing for 
homogeneous thermal dose distribution and improving imaging techniques able to correlate 
thermal maps of tumors to the clinical outcome of patients (Dewhirst et al., 2010).  
5. Non invasive imaging of tumor oxygenation and perfusion 
The study of magnetic resonance (MR) markers over the past decade has provided evidence 
that the tumor microenvironment and hemodynamics play a major role in determining 
therapy outcome. Therefore, the identification of relevant non-invasive imaging endpoints is 
of crucial importance in the management of cancer patients. Improvement of the therapeutic 
index was evidenced in numerous preclinical studies that used multimodal imaging. The 
impact of non-invasive imaging in oncology extends from guiding preclinical development 
of targeted biomarkers and therapeutic agents, to assisting in the diagnosis and staging of 
tumors in the clinic, as well as monitoring the therapeutic response. 
5.1 Tumor oxygenation measurements 
There is a critical need for developing dynamic, non-invasive methods for direct oxygen 
mapping in the clinical practice. Although hypoxia is recognized as a crucial issue in many 
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disorders and in treatment response, the lack of easy-to-use and efficient methods to 
quantify oxygen deprivation hampers further pathophysiological understanding and 
restricts the clinical implementation of oxygen mapping techniques resulting in the absence 
of gold standard for measuring hypoxia in the day-to-day practice (Tatum et al., 2006). 
Below is a non exhaustive review of the most relevant non invasive methods able to assess 
tumor hemodynamic parameters. Methods to measure absolute pO2 mostly encompass EPR 
oximetry and 19F relaxometry whereas indirect methods include Blood Oxygen Level-
Dependent (BOLD) MRI, Oxygen enhanced relaxation MRI, Oxygen enhanced longitudinal 
relaxation MRI and positron emission tomography (PET) tracers retained in hypoxic 
regions. Of note, our group has also developed innovative methods to assess tumor oxygen 
consumption in vitro and in vivo, which have been reviewed elsewhere (Jordan & Gallez, 
2011). 
5.1.1 Electron Paramagnetic Resonance (EPR) oximetry 
EPR is a MR method that detects only species containing unpaired electrons (Gallez & 
Swartz, 2004a). One of the numerous applications of EPR is in vivo oximetry. Molecular 
oxygen is a triplet radical that possesses two unpaired electrons which are responsible for its 
paramagnetism. However, EPR is not able to detect oxygen itself when dissolved in fluids 
near room temperature: in biological systems, the output signal lines are so broadened as to 
be undetectable. Indirect methods exist. Most of these methods rely on the paramagnetic 
properties of molecular oxygen, which acts as an efficient relaxer for other paramagnetic 
species (Gallez et al., 2004b). The enhancement of relaxation rates scales linearly with the 
concentration of oxygen over a wide range of oxygen tensions. The lack of detectable levels 
of endogenous paramagnetic species makes it necessary to use exogenous paramagnetic 
materials. Variations in pO2 of less than 1mmHg can be detected using particulate materials. 
While EPR spectroscopy provides local measurements, EPR imaging techniques provide 
spatially resolved measurements of these materials. The spatial distribution of free radicals 
can be performed utilizing magnetic field gradients in a manner similar to that of MRI. 
Spectral–spatial EPR imaging encodes both the spatial distribution of the spin probe and the 
spectral information, which allows the mapping of molecular oxygen (Kuppusamy et al., 
2003). For this purpose, the use of soluble EPR materials such as trityl radicals is more 
convenient as they can diffuse in the whole tissue.  
EPR oximetry was compared with other methods that provide direct or indirect 
measurements of tumor oxygenation: with polarographic electrodes, the distribution of 
nitroimidazoles, the BOLD effect in MRI, and pO2 recordings using OxyLite (reviewed in 
Gallez et al., 2004b). Two major challenges are now considered for moving this technology 
into the clinic: (i) assuring biocompatibility of the oxygen sensors in humans and (ii) 
modifying the instruments so that they can be used for humans instead of small animals 
(Swartz et al., 2004). 
5.1.2 19F relaxometry 
19F NMR spectroscopy and imaging of perfluorocarbon (PFC) emulsions (hydrocarbons 
with protons having been replaced with fluorine nuclei) has been extensively exploited to 
measure the oxygen tension of biological systems in preclinical studies. The 19F MR signal of 
the PFC is sensitive to the pO2 of the surrounding tumor tissue, and acts as an oximeter. The 
principle behind 19F MR oximetry relies on the linear increase of the NMR spin-lattice 
relaxation rate R1 (=1/T1) of PFC emulsions with increasing oxygen tension (Mason et al. 
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1996). 19F MR oximetry provides a sensitive measure of tissue oxygen tension and is a 
powerful approach for monitoring tumor hypoxia. Several PFCs have been used for NMR 
oximetry, but hexafluorobenzene (HFB) is preferred (Mason et al., 1996; Zhao, et al., 2004) 
because it has a six-fold symmetry with a single 19F NMR resonance, and a low sensitivity to 
temperature. Its spin lattice relaxation rate is highly sensitive to pO2 and exhibits a linear 
relationship across the entire range of tissue oxygenation. 
Mason and colleagues have been successfully developing fluorocarbon relaxometry using 
echo planar imaging for dynamic oxygen mapping (FREDOM) MRI following direct 
intratumoral injection of the oxygen reporter molecule HFB. Our group further developed 
an MRI fluorocarbon oximetry technique using snapshot inversion recovery with an 
improved temporal resolution of 1.5 minutes (vs. 6.5 minutes for FREDOM) (Jordan et al., 
2009). Our method therefore provides a rapid way to map tumor oxygenation and is 
particularly suitable to monitor acute changes of pO2 in tumors, including spontaneous 
fluctuations (Jordan et al., 2009; Magat et al., 2010). The translation to the clinic is currently 
limited by the lack of development of coils in the clinical setting, and the lack of 
characterization of PFCs in humans. 
5.1.3 Blood Oxygen Level Dependent (BOLD) MRI 
Functional MRI (fMRI) was first developed as an indirect method of imaging brain activity 
at high temporal resolution (Ogawa et al., 1990). The relative decrease in deoxyhemoglobin 
concentration, which has a paramagnetic effect, can be detected by MRI as a weak transient 
rise in the T2* weighted signal. This is the BOLD contrast principle. Apart from its very large 
application in neuroscience, the use of BOLD contrast in tumors brought with it new 
challenges of understanding and interpretation. Since then, BOLD MRI has become a useful 
tool for addressing important questions regarding the pathophysiology of tumors. 
However, it has both advantages and disadvantages. One advantage of BOLD MRI is that it 
is noninvasive and can be used to monitor real time changes of tumor oxygenation during 
pharmacological treatments or to monitor spontaneous fluctuations in experimental tumors 
(Baudelet & Gallez 2002; Baudelet et al., 2004). It does not require externally administered 
contrast medium or radioactive isotopes, it can be repeated as necessary, and flow 
dependence can be decoupled. BOLD MRI, in combination with hypercapnia and hyperoxia, 
is also an attractive method for assessing maturation and the functional state of tumor blood 
vessels (Baudelet et al., 2006). As for disadvantages, BOLD MRI is unfortunately a non-
quantitative method for monitoring tumor pO2. This is the result of the extreme sensitivity 
of changes in R2* to the basal state of tumor oxygenation and blood volume fraction. The 
intra and intertumoral distribution of these parameters may be greatly heterogeneous, 
making it very difficult to compare estimated pO2 changes between two regions or 
individuals. Even more problematic is the fact that the change in R2* is not always indicative 
of the change in pO2. Concomitant changes in blood volume, blood pH and metabolic status 
can lead to smaller-than-expected or even negative changes in R2* (Baudelet & Gallez, 2002). 
Similarly, changes in oxygen consumption rate has been described to result in a lack of 
change in R2* even though absolute pO2 is increased (Jordan et al., 2006b).  
5.1.4 Oxygen enhanced longitudinal relaxation MRI 
An alternative MRI technique for evaluating change in tumor oxygenation using 
endogenous contrast relies in the increase of the proton longitudinal relaxation rate (R1) of 
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water containing oxygen, due to the paramagnetic properties of oxygen. The measured 
change in R1 is, in theory, proportional to the change in tissue oxygen concentration 
(O’Connor et al., 2007, 2009). Studies have indeed demonstrated that oxygen-enhanced MRI 
produces measurable signal changes in normal tissues in patients and is feasible on 
conventional clinical scanners. Therefore, oxygen-induced increase in R1 has the potential to 
provide noninvasive measurements of change in tumor oxygen concentration, distinct from 
BOLD imaging. Nevertheless, the technique still lacks in sensitivity and the measured delta 
R1 may include errors resulting from changes independent of tissue oxygen content, such as 
alteration in blood flow or tissue H2O content (O’Connor et al., 2009).  
5.1.5 Hypoxia assessed by Positron Emission Tomography (PET)  
 18F-labeled fluoromisonidazole (18F-MISO) is probably the most widely used PET imaging 
agent for hypoxia. 18F-MISO accumulates in tissues by binding to intracellular 
macromolecules when pO2 < 10 mm Hg. Retention within tissues is dependent on 
nitroreductase activity (that is, on the reduction status of a NO2 group on the imidazole 
ring) and accumulation in hypoxic tissues over a range of blood flows has been observed 
(Tatum et al., 2006). 18F-MISO is only sensitive to the presence of hypoxia in viable cells: 18F-
MISO is not retained in necrosis because the electron transport chain that reduces the 
nitroimidazole to a bioreductive alkylating agent is no longer active (Padhani et al., 2007). 
Nevertheless, 18F-MISO PET is able to monitor the changing hypoxia status of lung tumors 
during radiotherapy (Koh et al., 1995). Studies in sarcoma (Rajendran et al., 2003) and head 
and neck cancer (Rajendran et al., 2004) have demonstrated a correlation of 18F-MISO uptake 
with poor outcome to radiation and chemotherapy. Other 18F labeled nitroimidazoles are 
currently evaluated, including EF3 and fluoroazomycin arabinoside (FAZA), for example 
(Tatum et al., 2006). 
5.2 Tumor perfusion measurements 
Microvascular parameters such as permeability and perfusion are of particular interest in 
the context of the abnormal tumor microvascular network. Useful imaging systems have 
been developed to monitor angiogenesis and the microvasculature in vivo, including DCE-
MRI (Choyke, et al. 2003), PET and Single Photon Emission Computed Tomography 
(SPECT), CT, Doppler ultrasound, and optical imaging methods (see Jennings, et al., 2008). 
5.2.1 Dynamic Contrast Enhanced MRI 
DCE-MRI consists in the acquisition of serial MR images before, during, and after the 
administration of an intravenous contrast agent (CA) to produce time series images that 
enable pixel-by-pixel analysis of contrast kinetics within a tumor. Pharmacokinetic models 
provide a means of summarizing contrast enhancement data in terms of parameters that 
relate to the underlying vascular anatomy and physiology. As described by Tofts et al. 
(1999), the essential features of a variety of models are covered by the generalized kinetic 
model. Most methods of analyzing dynamic contrast-enhanced T1-weighted data acquired 
with low molecular contrast medium use a compartmental analysis to obtain some 
combination of the three principal parameters: the transfer constant Ktrans in min-1 (volume 
transfer constant between blood plasma and ESS), the rate constant Kep in min-1 (rate 
constant between blood plasma and extravascular extracellular space [ESS]) and the volume 
of ESS per unit volume of tissue space, Vp (no unit). DCE-MRI has evolved from an 
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experimental technique to a clinically feasible adjunct procedure that can be integrated into 
a standard morphologic imaging protocol. It does provide unique non-invasive functional 
information on the properties of tumors related to microcirculation (distribution volume, 
permeability, and perfusion). This information can improve diagnostic characterization, the 
follow-up of therapy, and tumor staging; and it provides tools to facilitate advanced 
molecular imaging. Preclinical and clinical studies suggest that a successful antivascular 
treatment results in a decrease in the rate of enhancement along with a decreased amplitude 
and a slower washout, and that poor response can result in persistent abnormal 
enhancement (Gillies et al., 2002). 
5.2.2 Positron emission tomography 
Generally, PET measures of tumor perfusion have used (15O)-labeled radiotracers. The so-
called steady state method requires inhalation of 15O-CO2 and the dynamic method requires 
an intravenous bolus injection of 15O-H2O (Jennings et al., 2008). A requirement for 
quantification of perfusion using dynamic methods is an accurate determination of an 
arterial input function, which can be obtained non-invasively in a purely arterial region of 
interest, such as the aorta. 
5.2.3 Computed tomography 
In X-ray CT, the tissue contrast is based on variable attenuation coefficients of the object 
absorbing the X-rays. Hemodynamic parameters may be extracted from dynamic changes in 
X-ray attenuation caused by the intravenous injection of an iodinated contrast agent. 
Perfusion CT data can deliver quantitative hemodynamic information, such as blood 
volume, blood flow, permeability surface-area product and mean transit time (MTT) 
(Jennings et al., 2008). 
5.2.4 Doppler ulstrasound 
There are several different ultrasonic approaches designed specifically to measure blood 
flow including transit time, continuous-wave Doppler, pulsed and color Doppler, and 
power Doppler flowmeters, requiring the use of microbubbles (filled with air, 
perfluorocarbon, sulfur hexafluoride or nitrogen), which expand and contract because of 
pressure from the acoustical transmit pulse, and the primary mode of echogenicity is the 
impedance mismatch between the microbubble–blood interface, making them significantly 
more echogenic than normal tissue. Typical parameters that are estimated using Doppler 
ultrasound include: percent intratumor contrast agent uptake, enhancement timing and 
pattern, percent blood volume fraction, red blood cell velocity, and perfusion; depending on 
the type of study and tracer used (Jennings et al., 2008). 
6. Conclusions 
Heterogeneities in blood flow and oxygenation are key characteristics of solid tumors and 
constitute a therapeutic challenge when these tumors are treated with radiotherapy or 
systemic therapies. Because oxygen stabilizes DNA lesions, tumors become increasingly 
resistant to radiotherapy and to several forms of chemotherapy when the tumor pO2 
decreases below a threshold of 10 mmHg. In the past decades, basic and preclinical 
researches have identified several adjuvant treatments aimed at transiently increasing tumor 
oxygenation at the time of radiotherapy. Their identification was based on an increasing 
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understanding of the origins of tumor hypoxia, which logically opened two main avenues: 
co-treatments designed to (1) improve the oxygen supply from blood vessels at the time of 
radiotherapy (with different strategies such as increasing the O2 content of blood, inducing 
tumor-specific vasodilation, or normalizing vascular structures), and (2) reduce the rate of 
O2 consumption by tumor cells through metabolic interventions. Theoretical models now 
validated preclinically have revealed that the metabolic strategy has the highest impact on 
tumor radiosensitivity, but the best opportunity still resides in treatments combining both 
vascular and metabolic effects, as perfectly illustrated with hyperthermia. Most systemic 
anticancer treatments are also confronted to the difficulty to reach a target often located at 
distance from blood vessels, thus indicating that in this case increased tumor perfusion (i.e., 
decreased resistance to flow) could improve tumor bioavailability. NO-donors, ET-1 
inhibitors, radiotherapy or heat as adjuvant provascular treatments, or anti-angiogenic 
therapies and chemotherapy used in a ‘vascular normalization’ mode, have all 
demonstrated their capacity to chemosensitize tumors in preclinical settings. Most of the 
adjuvant treatments described here could theoretically be exploited therapeutically by the 
off-label use of existing FDA-approved drugs, but it has also become evident that a given 
tumor in a given patient would respond differently than the tumor of the patient next-door. 
It is therefore urgent to develop and implement in the clinics imaging techniques able not 
only to provide predictive markers but also biological markers of the response to such 
combinational interventions. The MR and PET techniques that we reviewed here are among 
the most-sensitive non-invasive techniques having proved their highly valuable power as to 
measure changes in tumor perfusion and oxygenation preclinically. Current challenges 
include the FDA approval of exogenous tracers and sensors when needed, scaling-up tools 
initially dedicated for small laboratory animals and adapting imaging protocols to the 
clinical situation, the transfer to the clinics of the expertise needed for protocol design and 
data interpretation and, as importantly,  a careful consideration of societal cost issues.    
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